CHICAGO – Changes in the structure and function of the left ventricle help explain how SGLT-2 inhibitors can improve cardiovascular health, as demonstrated by the EMPA-HEART Cardiolink-6 test.
Patients with type 2 diabetes mellitus with good coronary artery disease and with no cardiac insufficiency had an increased incidence of left abortion mass index of placebo (Jardiance) in placebo placenta (-2.6 g / m2 vs -0.01 g / m2, P= 0.01) and LV mass regression with Cardiac MRI (-4,71 versus -0,39 g), including Subodh Vermma (MD), PhD, Subodh Verma, and colleagues at the University of Toronto.
At the Annual Meeting of the American Heart Association (AHA), at the presentation presentation, differences remained in spite of the fact that the height and weight of the researchers were indexed.
"These data contribute to early, statistical, and clinically significant recurrent rebounding of the SGLT-2 inhibitor empagliphlois, which can benefit from cardiovascular and heart failure detected in EMPA-REG OUTCOME tests and other SGLT-2 inhibitory studies."
In 2015 EMPA-REG researchers have shown that empaglifloz reduces the risk of cardiovascular events, especially cardiovascular mortality and cardiac insufficiency. However, the mechanism of SGLT-2 inhibitors can lead to the benefit of cardiovascular disease remains to this day.
Reinstatement is just one of several recommended mechanisms; Another important feature of the diuresis was explained by Doctor of Northwest Medicine in Chicago, Donald Lloyd-John.
Other possible mechanisms include a decrease in intrauterine swelling; Reduced preload and load accompanying the voltage of the lower voltage wall; and inhibition of cardiac-sodium hydrogen exchange, Vermma noted.
The hematocrit level in EMPA-HEART was induced by SGLT-2 inhibition (+2,4% vs + 0,4% P= 0.006). Outpatient blood pressure monitoring was performed with empaglyphosine (-7,9 -0,7 mmNg, P= 0.003); Unlike diastolic blood pressure reduction, there was no difference between the drug and placebo (-2.0-0.8 mmHg, P= 0.22).
On the other hand, LV 's recent systolic volume index and LV' s recent diastolic volume index were not the preferred results for cardiac MRI results. The LV Ejection Fraction (LVEF) is empagfluxinated (+2,2% -0,01, P= 0.07).
NT-proBNP, troponin I, and dissolved ST2 levels did not affect SGLT-2 inhibition, but Vermma noted that the biomarker was low in healing and did not cure.
Also, Empagliphlins could not dent themselves during adverse events.
EMPA-HEART includes patients with type 2 diabetes mellitus with ages 40-80 years and A1S in 6.5-10% range. Researchers had pre-coronary revascularization or MI. All of the anti-hyperglycemic therapy was stable.
This included SGLT-2 inhibitor, GLP-1 receptor agonist or Sahagllipin (Onglyza). Patients are not eligible for any other criterion if they have low or low LVEF levels or New York Heart Association IV classifier classification.
Of the 423 people surveyed, 97 were found to have no interest in attendance and reasons for their removal.
Teams are at the basic level, while the mean age at BMI 27 and LV of 63 years old in cognition is about 60 g / m2. Almost all participants were metformin, statins and angiotensin enzyme inhibitors or receptor blockers of angiotensin II.
According to the subgroup analysis, the LV mass index is> 60 g / m2 After 6-month empagli-phosynin administration, this metric has largely been major abbreviations (P= 0.007).
However, Vermma was a small sample in EMEPA-HERE and was observed shortly.
"This is a very important mechanical research," says Dr. Brigam and Women's Hospital, BGU. Elliott Anman. "This reduction in LV mass is an important control because the LV mass is an independent predictor of cardiovascular events, including heart failure."
Anthracym suggested that systolic blood pressure and hematocrit due to empagliflloin in EMMA-HEART would lead to a "favorable" condition in patients preloading and subsequent loading.
According to Antmain, there is DECLARE-TIMI 58 study of Dacklermine (Fahrheline) with diabetes and DGP-2 inhibitor, which reduces kidney drainage.
The research was supported by Boehringer Ingelheim.
Vermma Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, Valeant and Sanofi.
Hartmann denied proper relationships with the industry.
2018-11-11T15: 30: 00-0500